Pfizer Inc. (PFE) Aandelenanalyse

Bedrijfsoverzicht

Pfizer Inc. is a major biopharmaceutical entity that discovers, develops, manufactures, markets, distributes, and sells products across the United States and international markets. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - General industry, which characterizes its focus on the production and commercialization of pharmaceutical solutions. This large-scale operation employs approximately 75,000 individuals and holds a total market capitalization of $153.13 billion. The annual revenue generated by the company reaches $62.58 billion, figures that collectively indicate Pfizer's position as a dominant global player with significant market penetration and operational scale within the healthcare landscape.

Financiële gezondheid

Pfizer reported a trailing twelve-month revenue of $62.58 billion and net income of $7.75 billion, while its EBITDA stands at $25.72 billion. The substantial gap between the revenue figure and the net income reveals a cost structure where expenses, including cost of goods sold, operating expenses, and taxes, consume approximately 87.6% of total revenue before arriving at the final profit. The company generated free cash flow of $13.43 billion, which demonstrates robust financial flexibility allowing for capital expenditures, debt repayment, or potential strategic acquisitions without immediate reliance on external financing. Profitability analysis shows a gross margin of 75.8%, indicating high efficiency in production relative to sales prices; an operating margin of 23.9% reflects effective control over administrative and selling expenses; and a profit margin of 12.4% confirms the final profitability after all costs. On the balance sheet, Pfizer holds $13.60 billion in cash against $67.65 billion in total debt, resulting in a debt-to-equity ratio of 77.96, which suggests a leveraged capital structure rather than a conservative one. Liquidity is assessed via a current ratio of 1.16, indicating that the company possesses just enough current assets to cover its current liabilities, suggesting a tight but manageable short-term liquidity position. Furthermore, the return on equity is 8.9% and the return on assets is 5.7%, metrics that reveal management's effectiveness in generating returns for shareholders relative to the equity invested and the total assets employed in the business.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is 19.79, while the forward P/E ratio is significantly lower at 9.56. This wide disparity between the trailing and forward multiples implies that the market expects a substantial increase in future earnings or that the current earnings are temporarily depressed, driving the valuation down for future expectations. The price-to-book ratio stands at 1.77, which indicates that the market values the company at a premium of 77% over its book value, reflecting the intangible value of patents, brand equity, and future growth potential not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 2.45 and an EV/EBITDA of 8.06, figures that suggest the company is priced reasonably relative to its sales volume and enterprise earnings compared to peers, despite the high debt load. The stock has traded between a 52-week high of $28.75 and a 52-week low of $21.87, providing a range within which the current price must be interpreted relative to historical volatility. The beta value of 0.39 indicates that the stock is significantly less volatile than the broader market, moving with less intensity during market swings.

Growth & Income

Pfizer experienced a revenue growth rate of -1.2% year-over-year, while earnings growth data is currently listed as N/A in the available facts. The contraction in revenue suggests a challenging period for top-line expansion, whereas the absence of reported earnings growth figures prevents a direct comparison of profitability expansion versus top-line performance at this specific moment. Regarding income, the company offers a dividend yield of 6.4%, but the payout ratio is 126.5%. This payout ratio exceeding 100% indicates that the company is paying out more in dividends than its net income, which generally signals a reliance on cash reserves or capital raising to fund these distributions rather than organic earnings. Given the high payout ratio and negative revenue growth, the dividend sustainability is currently dependent on non-operating cash flows or asset liquidation rather than core earnings generation. Overall, the growth and income profile presents a scenario of mature capital allocation where high dividend returns are offered alongside a contraction in operational revenue and a leveraged balance sheet structure.